OncoMatch/Clinical Trials/NCT06458712
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Is NCT06458712 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DSB2455 for advanced malignancies with homologous recombination deficiency (hrd) (breast, ovarian, mcrpc, brain metastases).
Treatment: DSB2455 — Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage inter-participant Dose Escalation Phase followed by a Dose Expansion Phase.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: parp1-selective inhibitor
Cannot have received: systemic anti-cancer therapy
Lab requirements
Cardiac function
Impaired cardiac function or clinically significant cardiac disease [excluded]
Impaired cardiac function or clinically significant cardiac disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale Cancer Center - Yale New Haven Hospital · New Haven, Connecticut
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify